The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles

Climate Crisis
George Monbiot: Opinion Insectageddon: farming is more catastrophic than climate breakdown
At least Monsanto, Bayer and the other multinational pesticide and GMO seed producers are still earning billions. Like Peter Thiel, those making the profits are probably buying estates in New Zealand, where they can go when the environmental […]

EU politics
El Nacional.Cat: Poland and Romania align with Spain against Puigdemont over EU justice questions
EU countries with submissions on exiled Catalan politicians’ case have presented their arguments to Luxembourg court Read here

EU politics
Bloomberg: A Truly Terrible Idea for Deutsche Bank
January 21, 2019
Mathew D. Rose
EU politics, EU-Institutions, Finance, Financial Institutions, National Politics
0
A Commerzbank merger would make a mockery of the EU’s hopes to avoid lenders that are “too big to fail” – and the bloc’s plans for a banking union. Read here
Be the first to comment